Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients
BackgroundEfgartigimod was approved in Japan in January 2022 for the treatment of generalized myasthenia gravis (gMG), regardless of antibody status. This case series describes a real-world experience in Japan of efgartigimod treatment for gMG patients with diverse backgrounds.MethodsWe retrospectiv...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2024-10-01
|
| Col·lecció: | Frontiers in Neurology |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fneur.2024.1472845/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|